Terns Pharma Analyst Ratings
Terns Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/27/2023 | 164.55% | Mizuho | $17 → $10 | Maintains | Buy |
08/10/2023 | 111.64% | HC Wainwright & Co. | $11 → $8 | Maintains | Neutral |
08/09/2023 | 191.01% | JP Morgan | $10 → $11 | Maintains | Neutral |
08/08/2023 | 508.47% | Roth MKM | → $23 | Reiterates | → Buy |
07/26/2023 | 349.74% | JMP Securities | → $17 | Reiterates | Market Outperform → Market Outperform |
06/30/2023 | 508.47% | Roth MKM | → $23 | Reiterates | Buy → Buy |
06/30/2023 | 349.74% | JMP Securities | → $17 | Reiterates | Market Outperform → Market Outperform |
06/30/2023 | 323.28% | Mizuho | → $16 | Reiterates | Buy → Buy |
06/27/2023 | 323.28% | Mizuho | → $16 | Reiterates | Buy → Buy |
06/22/2023 | 323.28% | Mizuho | → $16 | Initiates Coverage On | → Buy |
06/07/2023 | 376.19% | Jefferies | → $18 | Initiates Coverage On | → Buy |
05/31/2023 | 508.47% | Roth MKM | → $23 | Initiates Coverage On | → Buy |
05/19/2023 | 191.01% | HC Wainwright & Co. | → $11 | Reiterates | Neutral → Neutral |
05/16/2023 | 164.55% | JP Morgan | $9 → $10 | Maintains | Neutral |
05/16/2023 | 349.74% | JMP Securities | $17 → $17 | Reiterates | Market Outperform → Market Outperform |
05/08/2023 | 376.19% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
03/29/2023 | 349.74% | JMP Securities | → $17 | Reiterates | → Market Outperform |
03/29/2023 | 138.1% | JP Morgan | $6 → $9 | Maintains | Neutral |
03/29/2023 | 191.01% | HC Wainwright & Co. | $7 → $11 | Maintains | Neutral |
02/14/2023 | 349.74% | JMP Securities | → $17 | Initiates Coverage On | → Market Outperform |
02/07/2023 | 402.65% | UBS | → $19 | Initiates Coverage On | → Buy |
12/29/2022 | 85.19% | HC Wainwright & Co. | $6 → $7 | Maintains | Neutral |
12/20/2022 | 270.37% | Goldman Sachs | $9 → $14 | Maintains | Buy |
09/28/2022 | 138.1% | Goldman Sachs | $4 → $9 | Maintains | Buy |
09/12/2022 | 58.73% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Neutral |
03/23/2022 | 58.73% | JP Morgan | $19 → $6 | Downgrades | Overweight → Neutral |
08/18/2021 | 402.65% | JP Morgan | $32 → $19 | Maintains | Overweight |
03/02/2021 | 746.56% | JP Morgan | → $32 | Initiates Coverage On | → Overweight |
03/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
03/02/2021 | 667.2% | Goldman Sachs | → $29 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/27/2023 | 164.55% | 瑞穗市 | 17 美元 → 10 美元 | 維護 | 買 |
08/10/2023 | 111.64% | HC Wainwright & Co. | 11 美元 → 8 美元 | 維護 | 中立 |
08/09/2023 | 191.01% | 摩根大通 | 10 美元 → 11 美元 | 維護 | 中立 |
08/08/2023 | 508.47% | Roth MKM | → 23 美元 | 重申 | → 購買 |
07/26/2023 | 349.74% | JMP 證券 | → 17 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
06/30/2023 | 508.47% | Roth MKM | → 23 美元 | 重申 | 購買 → 購買 |
06/30/2023 | 349.74% | JMP 證券 | → 17 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
06/30/2023 | 323.28% | 瑞穗市 | → 16 美元 | 重申 | 購買 → 購買 |
06/27/2023 | 323.28% | 瑞穗市 | → 16 美元 | 重申 | 購買 → 購買 |
06/22/2023 | 323.28% | 瑞穗市 | → 16 美元 | 啓動覆蓋範圍開啓 | → 購買 |
06/07/2023 | 376.19% | 傑富瑞集團 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
05/31/2023 | 508.47% | Roth MKM | → 23 美元 | 啓動覆蓋範圍開啓 | → 購買 |
05/19/2023 | 191.01% | HC Wainwright & Co. | → 11 美元 | 重申 | 中性 → 中性 |
05/16/2023 | 164.55% | 摩根大通 | 9 美元 → 10 美元 | 維護 | 中立 |
05/16/2023 | 349.74% | JMP 證券 | 17 美元 → 17 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
05/08/2023 | 376.19% | BMO Capital | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
03/29/2023 | 349.74% | JMP 證券 | → 17 美元 | 重申 | → 市場跑贏大盤 |
03/29/2023 | 138.1% | 摩根大通 | 6 美元 → 9 美元 | 維護 | 中立 |
03/29/2023 | 191.01% | HC Wainwright & Co. | 7 美元 → 11 美元 | 維護 | 中立 |
02/14/2023 | 349.74% | JMP 證券 | → 17 美元 | 啓動覆蓋範圍開啓 | → 市場跑贏大盤 |
02/07/2023 | 402.65% | 瑞銀(UBS) | → 19 美元 | 啓動覆蓋範圍開啓 | → 購買 |
12/29/2022 | 85.19% | HC Wainwright & Co. | 6 美元 → 7 美元 | 維護 | 中立 |
2022 年 12 月 20 日 | 270.37% | 高盛 | 9 美元 → 14 美元 | 維護 | 買 |
2022 年 9 月 28 日 | 138.1% | 高盛 | 4 美元 → 9 美元 | 維護 | 買 |
09/12/2022 | 58.73% | HC Wainwright & Co. | → 6 美元 | 啓動覆蓋範圍開啓 | → 中立 |
03/23/2022 | 58.73% | 摩根大通 | 19 美元 → 6 美元 | 降級 | 超重 → 中性 |
2021 年 8 月 18 日 | 402.65% | 摩根大通 | 32 美元 → 19 美元 | 維護 | 超重 |
2021 年 2 月 3 日 | 746.56% | 摩根大通 | → 32 美元 | 啓動覆蓋範圍開啓 | → 超重 |
2021 年 2 月 3 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
2021 年 2 月 3 日 | 667.2% | 高盛 | → 29 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Terns Pharma (TERN)?
Terns Pharma(TERN)的目標價格是多少?
The latest price target for Terns Pharma (NASDAQ: TERN) was reported by Mizuho on November 27, 2023. The analyst firm set a price target for $10.00 expecting TERN to rise to within 12 months (a possible 164.55% upside). 23 analyst firms have reported ratings in the last year.
瑞穗於2023年11月27日公佈了Terns Pharma(納斯達克股票代碼:TERN)的最新目標股價。該分析公司將目標股價定爲10.00美元,預計TERN將在12個月內升至12個月內(可能上漲164.55%)。去年有23家分析公司公佈了評級。
What is the most recent analyst rating for Terns Pharma (TERN)?
Terns Pharma(TERN)的最新分析師評級是多少?
The latest analyst rating for Terns Pharma (NASDAQ: TERN) was provided by Mizuho, and Terns Pharma maintained their buy rating.
瑞穗對Terns Pharma(納斯達克股票代碼:TERN)的最新分析師評級由瑞穗提供,Terns Pharma維持買入評級。
When is the next analyst rating going to be posted or updated for Terns Pharma (TERN)?
Terns Pharma(TERN)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Terns Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Terns Pharma was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Terns Pharma的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Terns Pharma的最新評級是在2023年11月27日公佈的,因此您應該預計下一個評級將在2024年11月27日左右公佈。
Is the Analyst Rating Terns Pharma (TERN) correct?
Terns Pharma(TERN)的分析師評級是否正確?
While ratings are subjective and will change, the latest Terns Pharma (TERN) rating was a maintained with a price target of $17.00 to $10.00. The current price Terns Pharma (TERN) is trading at is $3.78, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但Terns Pharma(TERN)的最新評級維持不變,目標股價爲17.00美元至10.00美元。Terns Pharma(TERN)目前的交易價格爲3.78美元,超出了分析師的預期區間。